Glaucoma Treatment Market By Treatment Type (Medications, Laser Therapy, Surgical Treatment), By Drug Class (Prostaglandin Analogs, Beta-Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Rho Kinase Inhibitors, Combination Drugs), By Surgery Type (Trabeculectomy, Glaucoma Drainage Devices, Minimally Invasive Glaucoma Surgery (MIGS)), By End-User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Glaucoma Treatment Market was valued at USD 3.4 billion in 2024-e and will surpass USD 6.2 billion by 2030; growing at a CAGR of 10.5% during 2025 - 2030.

The glaucoma treatment market is witnessing steady growth due to the rising prevalence of glaucoma, an aging global population, and increasing awareness of early diagnosis and treatment. Glaucoma, a leading cause of irreversible blindness worldwide, requires long-term management, fueling demand for effective treatment options, including medications, laser therapy, and surgical interventions. The increasing adoption of minimally invasive glaucoma surgeries (MIGS) and advanced drug formulations is driving market expansion, with healthcare providers focusing on optimizing treatment outcomes and preserving patients’ vision.

Technological advancements, such as sustained-release drug delivery systems and innovative surgical techniques, are further revolutionizing glaucoma management. With growing research into neuroprotective therapies and gene-based treatments, the market is expected to evolve rapidly. Additionally, supportive government initiatives, rising healthcare expenditure, and increased access to ophthalmic care in developing regions contribute to market growth. As the disease burden continues to rise, the demand for novel and patient-friendly treatment solutions will drive significant advancements in the market.

Medications is the Largest Treatment Type Owing to Widespread Use and Non-Invasive Nature

Medications remain the most widely used treatment for glaucoma due to their ease of administration, effectiveness in intraocular pressure (IOP) reduction, and non-invasive nature. Prescription eye drops, including prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors, serve as the first-line treatment for most glaucoma patients, delaying disease progression and preventing optic nerve damage.

The growing availability of combination drug therapies, which improve patient adherence by reducing dosing frequency, has further strengthened the dominance of the medications segment. Additionally, pharmaceutical companies are focusing on developing novel drug delivery mechanisms, such as sustained-release implants and microneedle-based delivery systems, to enhance therapeutic outcomes and minimize side effects. With continuous innovations in pharmacological treatment options, medications are expected to remain the cornerstone of glaucoma management.

Prostaglandin Analogs is the Largest Drug Class Owing to Superior Efficacy in Intraocular Pressure Reduction

Prostaglandin analogs hold the largest market share among drug classes due to their superior efficacy in lowering intraocular pressure (IOP), the primary risk factor for glaucoma. These drugs, including latanoprost, bimatoprost, and travoprost, enhance the outflow of aqueous humor, effectively reducing IOP with once-daily dosing, leading to higher patient compliance.

The preference for prostaglandin analogs is further driven by their long-lasting effects and minimal systemic side effects compared to other drug classes. Additionally, advancements in formulation technologies, such as preservative-free variants and combination therapies, are expanding their adoption. As research continues to optimize their efficacy and safety profiles, prostaglandin analogs will remain the dominant choice in glaucoma pharmacotherapy.

Minimally Invasive Glaucoma Surgery (MIGS) is the Fastest Growing Surgery Type Owing to Lower Risk and Faster Recovery

Minimally invasive glaucoma surgery (MIGS) is emerging as the fastest-growing surgical treatment due to its ability to reduce intraocular pressure with minimal trauma, shorter recovery time, and fewer complications compared to traditional glaucoma surgeries. MIGS procedures, which include microstents and canaloplasty, provide effective treatment options for mild-to-moderate glaucoma patients who do not respond well to medications alone.

The growing adoption of MIGS is driven by increasing patient preference for less invasive procedures and ophthalmologists’ growing confidence in these advanced techniques. Additionally, continuous innovations in MIGS devices and the integration of robotic-assisted surgical tools are further propelling market expansion. With ongoing clinical advancements and rising demand for safer surgical alternatives, MIGS is expected to witness significant growth in the coming years.

Hospitals is the Largest End-User Owing to Advanced Surgical Facilities and High Patient Influx

Hospitals represent the largest end-user segment in the glaucoma treatment market due to their advanced ophthalmic care facilities, access to skilled specialists, and availability of comprehensive treatment options. As glaucoma management often requires a combination of medications, laser therapy, and surgical interventions, hospitals serve as key centers for both routine and advanced glaucoma care.

The growing number of hospital-based ophthalmology departments and the expansion of specialized eye care centers have further driven the dominance of this segment. Additionally, hospitals are increasingly adopting advanced surgical techniques, such as robotic-assisted glaucoma surgeries and AI-powered diagnostic tools, enhancing patient outcomes. With the rising burden of glaucoma and increasing healthcare investments in ophthalmology, hospitals will continue to play a crucial role in glaucoma treatment.

North America is the Largest Region Owing to High Disease Awareness and Advanced Healthcare Infrastructure

North America leads the glaucoma treatment market due to high disease awareness, a well-established healthcare system, and strong investments in ophthalmic research. The region has a significant prevalence of glaucoma, especially among the aging population, driving demand for advanced treatment options. Additionally, the presence of leading pharmaceutical and medical device companies accelerates innovation in drug formulations, laser therapies, and surgical procedures.

Government initiatives promoting early diagnosis, combined with favorable reimbursement policies, have further supported market growth in North America. The increasing adoption of AI-powered diagnostics and digital health solutions in ophthalmology is also enhancing patient management and treatment outcomes. As the region continues to advance in glaucoma research and treatment, North America is expected to maintain its market dominance.

Leading Companies and Competitive Landscape

The glaucoma treatment market is highly competitive, with key players such as Allergan (AbbVie), Novartis, Bausch + Lomb, Santen Pharmaceutical, and Glaukos Corporation leading the industry. These companies focus on continuous innovation in drug development, surgical devices, and laser technologies to enhance glaucoma management. Strategic partnerships, acquisitions, and new product launches play a vital role in strengthening market positions.

The market is also witnessing increased investment in AI-driven diagnostics and drug delivery innovations, offering more efficient and patient-friendly treatment options. Additionally, emerging biotechnology firms are developing neuroprotective and gene-based therapies, aiming to revolutionize glaucoma care. As competition intensifies, companies will continue to prioritize R&D efforts to address unmet medical needs and improve treatment outcomes in glaucoma management.

List of Leading Companies:

• Novartis AG
• Allergan (AbbVie Inc.)
• Pfizer Inc.
• Aerie Pharmaceuticals
• Bausch + Lomb
• Santen Pharmaceutical Co., Ltd.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Alcon Inc.
• Glaukos Corporation
• Iridex Corporation
• Sun Pharmaceutical Industries Ltd.
• EyePoint Pharmaceuticals, Inc.
• Bausch Health Companies Inc.
• Ellex Medical Lasers Ltd.

Recent Developments:

• In January 2025, Allergan (AbbVie) launched a new sustained-release glaucoma medication to improve patient adherence.
• In December 2024, Glaukos Corporation received FDA approval for its latest MIGS device for mild-to-moderate glaucoma treatment.
• In November 2024, Novartis announced positive phase III clinical trial results for an investigational glaucoma drug.
• In October 2024, Iridex Corporation expanded its laser glaucoma treatment portfolio with a next-generation laser trabeculoplasty system.
• In September 2024, Santen Pharmaceutical partnered with a biotech firm to develop a gene therapy approach for glaucoma treatment.

Report Scope: